JP2017526719A - オピオイド誘発性多幸症を減弱するためのシステム及び方法 - Google Patents

オピオイド誘発性多幸症を減弱するためのシステム及び方法 Download PDF

Info

Publication number
JP2017526719A
JP2017526719A JP2017513760A JP2017513760A JP2017526719A JP 2017526719 A JP2017526719 A JP 2017526719A JP 2017513760 A JP2017513760 A JP 2017513760A JP 2017513760 A JP2017513760 A JP 2017513760A JP 2017526719 A JP2017526719 A JP 2017526719A
Authority
JP
Japan
Prior art keywords
buprenorphine
opioid
administered
mcg
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526719A5 (enExample
Inventor
ヒューメル，ミシェル
カイル，ドナルド，ジェイ．
ホワイトサイド，ガース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of JP2017526719A publication Critical patent/JP2017526719A/ja
Publication of JP2017526719A5 publication Critical patent/JP2017526719A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017513760A 2014-09-12 2015-09-14 オピオイド誘発性多幸症を減弱するためのシステム及び方法 Pending JP2017526719A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462049989P 2014-09-12 2014-09-12
US62/049,989 2014-09-12
US201462065393P 2014-10-17 2014-10-17
US62/065,393 2014-10-17
PCT/US2015/049948 WO2016040934A1 (en) 2014-09-12 2015-09-14 Systems and methods for attenuating opioid-induced euphoria

Publications (2)

Publication Number Publication Date
JP2017526719A true JP2017526719A (ja) 2017-09-14
JP2017526719A5 JP2017526719A5 (enExample) 2018-10-25

Family

ID=55453711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513760A Pending JP2017526719A (ja) 2014-09-12 2015-09-14 オピオイド誘発性多幸症を減弱するためのシステム及び方法

Country Status (11)

Country Link
US (2) US20160074387A1 (enExample)
EP (1) EP3190890A4 (enExample)
JP (1) JP2017526719A (enExample)
KR (1) KR20170052644A (enExample)
CN (1) CN107072204A (enExample)
AU (1) AU2015314714A1 (enExample)
CA (1) CA2961009A1 (enExample)
IL (1) IL251049A0 (enExample)
MA (1) MA40333A (enExample)
TW (1) TW201613590A (enExample)
WO (1) WO2016040934A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500316A (ja) * 2017-10-20 2021-01-07 パーデュー、ファーマ、リミテッド、パートナーシップ 医薬剤形

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
CA3068036A1 (en) * 2017-06-30 2019-01-03 Purdue Pharma L.P. Use to buprenorphine in combination with an opioid to treat pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109743A2 (en) * 2010-03-04 2011-09-09 Rand Jerry N Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain
WO2013156850A1 (en) * 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1613266A4 (en) * 2003-04-15 2009-05-06 Theraquest Biosciences Llc METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20090246265A1 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2817071C (en) * 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109743A2 (en) * 2010-03-04 2011-09-09 Rand Jerry N Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain
WO2013156850A1 (en) * 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500316A (ja) * 2017-10-20 2021-01-07 パーデュー、ファーマ、リミテッド、パートナーシップ 医薬剤形
JP7293209B2 (ja) 2017-10-20 2023-06-19 パーデュー、ファーマ、リミテッド、パートナーシップ 医薬剤形

Also Published As

Publication number Publication date
WO2016040934A1 (en) 2016-03-17
IL251049A0 (en) 2017-04-30
MA40333A (fr) 2016-03-17
AU2015314714A1 (en) 2017-03-09
KR20170052644A (ko) 2017-05-12
EP3190890A4 (en) 2018-04-25
EP3190890A1 (en) 2017-07-19
US20200276187A1 (en) 2020-09-03
US20160074387A1 (en) 2016-03-17
CA2961009A1 (en) 2016-03-17
CN107072204A (zh) 2017-08-18
TW201613590A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
US20240350479A1 (en) Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
US20200276187A1 (en) Systems and methods for attenuating opioid-induced euphoria
US10226457B2 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200512